BIOGEN INC.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $BIIB in the last 30 days.
See all $BIIB insider activity →Biogen (BIIB) anticipates a $284M pre-tax charge for Q3 2026, reducing GAAP and non-GAAP EPS by $1.65 and $1.70, respectively. Additionally, $35M in expected expenses will shift to Q4. The company notes that such charges are unpredictable and not forecasted.
Biogen's litifilimab showed continued improvement in CLE patients through week 52, with response rates rising for key metrics. The phase 2 AMETHYST Part A trial randomized 93 adults, with 59 receiving litifilimab. At week 16, 14.7% of litifilimab participants achieved clear or almost clear skin vs. 2.9% with placebo. The drug received FDA Breakthrough Therapy designation for CLE in January 2026. Phase 3 trials are ongoing.
Arrowhead's Alzheimer's drug reduced tau in a Phase I/IIa trial. J&J's posdinemab failed in Phase IIb. Eisai's etalanetug, Biogen's diranersen, TauRx's hydromethylthionine, and Annovis Bio's buntanetap are in development. The Alzheimer's market is projected to grow from $2.4bn to $14.7bn by 2033, with a CAGR of 20%.
Over the past 7 days, AlphAI's AI scored 22 news stories mentioning BIIB (BIOGEN INC.). Coverage has skewed bullish: 19 bullish, 1 neutral, and 2 bearish.
Recent BIIB coverage spans financial news, earnings and market movers.
Preliminary acquired in-process R&D charges are expected to pressure Q3 GAAP and non-GAAP earnings per share, shaping near-term valuation and estimates.
Positive phase 2 data may lift Biogen's stock as the drug advances toward phase 3.
Disappointing data may weigh on Biogen’s share price.
Positive trial data may boost Biogen's stock and drive further upside.
The clinical-data update supports the immunology pipeline narrative, but the piece flags valuation risk if multiple sclerosis erosion accelerates or key launches underwhelm.
AlphAI scores every news story that mentions BIIB with an AI model for sentiment and relevance, and aggregates insider trades from BIOGEN INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Biogen (BIIB) anticipates a $284M pre-tax charge for Q3 2026, reducing GAAP and non-GAAP EPS by $1.65 and $1.70, respectively. Additionally, $35M in expected expenses will shift to Q4. The company notes that such charges are unpredictable and not forecasted.
3 min readBiogen's litifilimab showed continued improvement in CLE patients through week 52, with response rates rising for key metrics. The phase 2 AMETHYST Part A trial randomized 93 adults, with 59 receiving litifilimab. At week 16, 14.7% of litifilimab participants achieved clear or almost clear skin vs. 2.9% with placebo. The drug received FDA Breakthrough Therapy designation for CLE in January 2026. Phase 3 trials are ongoing.
2 min readArrowhead's Alzheimer's drug reduced tau in a Phase I/IIa trial. J&J's posdinemab failed in Phase IIb. Eisai's etalanetug, Biogen's diranersen, TauRx's hydromethylthionine, and Annovis Bio's buntanetap are in development. The Alzheimer's market is projected to grow from $2.4bn to $14.7bn by 2033, with a CAGR of 20%.
2 min readBiotech stocks BIIB, RTSN, CON, HNGE, and HSTM reached 52-week highs on October 12, 2026. BIIB hit $230.49 after positive clinical data for Litifilimab. RTSN rose 7% to $11.32 post-IPO. CON reported Q2 revenue growth of 10% to $606M. HNGE saw Q2 revenue rise 53% to $212M and acquired Cylinder Health. HSTM's Q2 revenue grew 12.5% to $83.7M.
2 min readBiogen (BIIB) reported 52-week Phase 2 data for litifilimab, showing sustained improvements in skin activity and a consistent safety profile. The stock has gained 26.9% year-to-date and 56.0% over one year, though it has declined over 3 and 5 years. Analysts debate whether Biogen is 5% undervalued at $225.71, with a fair value estimate of $238.18, considering its growth pipeline and multiple sclerosis erosion risks.
5 min readU.S. stocks traded mixed on Monday, with the Dow rising over 200 points, while the Nasdaq fell due to semiconductor stock declines. Salesforce (CRM) shares climbed after a Bank of America upgrade and price target increase to $285. Micron (MU) and SanDisk (SNDK) fell amid China chip competition concerns. Oil prices rose on Russia-Ukraine tensions.
3 min readMemory chip stocks fell after China's CXMT announced next-gen memory chips. eBay rose 5% after Morgan Stanley upgraded it to a top pick with a $132 price target. Meta gained 3% on AI model speculation. Optical stocks declined post-AI rebound. Salesforce, First Solar, Biogen, SLM, and Mattel also saw moves due to analyst upgrades or market speculation.
5 min readBMO Capital raised its price target for Biogen (BIIB) to $220 from $218, citing strong turnaround performance. Shares are up 29% YTD, trading at $233.78. BMO noted potential catalysts and challenges, including Phase 3 trial results. Other analysts have also raised targets, with JPMorgan setting a $300 target. Biogen's stock is near its 52-week high.
5 min readTruist Securities previewed Q3 2026 earnings for eight biotech companies, highlighting Insmed (INSM), BridgeBio (BBIO), and Neurocrine (NBIX) for potential volatility. Insmed's Brinsupri forecast was reduced due to lower prescription trends. BridgeBio's revenue surged 202% to $713M with 94% gross margins. The FDA accepted BridgeBio's NDA for infigratinib, with analysts maintaining Buy ratings and price targets.
7 min readBofA upgraded Salesforce (CRM) to Buy with a $285 target, citing enterprise platform resilience. Raymond James upgraded Humana (HUM) to Outperform with a $520 target, noting Medicare Advantage growth. T-Mobile (TMUS) also upgraded to Outperform with a $170 target. Truist upgraded First Solar (FSLR) to Buy with a $270 target. JPMorgan upgraded Biogen (BIIB) to Overweight with a $300 target. Wells Fargo double-downgraded Adobe (ADBE) to Underweight with a $225 target.
6 min read
